Anti-Fibrinolytic Drugs - Mauritius

Mauritius

The Anti-Fibrinolytic Drugs market in Mauritius is anticipated to witness a significant rise in revenue, with projections indicating that it will reach US$1.26m by the year 2024.
Furthermore, it is expected to display a steady annual growth rate of 5.67% from 2024 to 2029, resulting in a market volume of US$1.66m by the end of the forecast period.
In terms of global comparison, United States is expected to generate the highest revenue in the Anti-Fibrinolytic Drugs market, reaching a staggering US$9,858.00m in 2024.
Mauritius has seen a surge in the demand for anti-fibrinolytic drugs, driven by an aging population and an increase in cardiovascular diseases.

Key regions: United Kingdom, Brazil, Europe, France, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The market for Anti-Fibrinolytic Drugs in Mauritius has been showing steady growth in recent years.

Customer preferences: Patients in Mauritius prefer Anti-Fibrinolytic Drugs due to their effectiveness in treating bleeding disorders. These drugs are widely used in surgical procedures, especially in cases where there is a high risk of excessive bleeding.

Trends in the market: The market for Anti-Fibrinolytic Drugs in Mauritius has been growing due to an increase in the number of surgical procedures being performed in the country. Additionally, the rising prevalence of bleeding disorders among the population has also contributed to the growth of the market.

Local special circumstances: Mauritius is a small island nation with a population of around 1.3 million people. The country has a well-developed healthcare system that provides universal access to healthcare services. The government of Mauritius has been investing heavily in the healthcare sector, which has led to the development of state-of-the-art medical facilities in the country. This has helped to increase the demand for Anti-Fibrinolytic Drugs in the country.

Underlying macroeconomic factors: Mauritius has a stable economy with a high level of economic growth. The country has a well-developed infrastructure and a skilled workforce. The healthcare sector in Mauritius is rapidly expanding, which has led to an increase in the demand for medical products and services. Additionally, the government of Mauritius has been implementing policies to encourage foreign investment in the country, which has led to the entry of several multinational pharmaceutical companies in the market. This has helped to increase the availability of Anti-Fibrinolytic Drugs in the country.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.